{"filings":[{"id":843400,"accession_number":"0001104659-26-070345","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2026-06-04T12:00:53+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cognition Therapeutics presents at Jefferies; outlines registrational path for DLB psychosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash ~$31.2M as of March 31, 2026; $25.6M remaining NIA grant funds; runway into Q2 2027.","SHIMMER Phase 2: 86% slowing of NPI-12 decline vs placebo; 89% slowing of hallucinations/delusions.","FDA Division of Psychiatry meeting held May 20, 2026; minutes expected June 2026; registrational study design being finalized.","Registrational plan: 9-month, 1:1 zervimesine 100mg vs placebo, endpoint NPI-2; open-label extension planned.","START Phase 2 in early Alzheimer's (545 pts) ongoing; topline data expected 2H 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563876,"accession_number":"0001104659-26-064863","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2026-05-21T11:34:37+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA meeting held May 20, 2026 to review Phase 2 SHIMMER study results and registrational study design.","Company believes it has a path forward for zervimesine (CT1812) to treat dementia with Lewy bodies patients with psychosis.","Formal FDA minutes expected in June 2026.","Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage company developing neurodegenerative disorder treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92942,"accession_number":"0001104659-26-057186","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics Q1 2026 Net Loss Narrowed to $4.6M, FDA Meeting Set for May 20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q1 2026 was $4.6M ($0.05/share), down from $8.5M ($0.14/share) in Q1 2025.","Cash, cash equivalents, and restricted cash were $31.2M as of March 31, 2026; NIA grant funds $25.6M.","FDA Division of Psychiatry meeting scheduled for May 20, 2026 to discuss registrational plans for zervimesine in DLB psychosis.","Topline results from Phase 2 START study (COG0203) in early Alzheimer's expected in 2027.","Presented two posters at AD/PD 2026 conference on zervimesine's effect and composite endpoint for DLB."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104194,"accession_number":"0001104659-26-034876","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.","Completed enrollment in Phase 2 START trial in early Alzheimer's; topline results expected in 2027.","FDA Division of Psychiatry meeting anticipated by mid-2026 to discuss registrational plan for zervimesine in DLB psychosis.","Launched expanded access program for DLB patients following a philanthropic donation.","Appointed Dr. David Weinstein as VP of clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104193,"accession_number":"0001104659-26-021904","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.","Phase 2 SHIMMER data showed 86% slowing of decline on NPI-12 vs placebo; no motor function worsening.","No approved medications for DLB psychosis; traditional antipsychotics are contraindicated.","Next study will use validated endpoints for neuropsychiatric symptoms; patients randomized to 100 mg zervimesine or placebo.","Company expects to meet with FDA Division of Psychiatry by midyear 2026 to discuss the program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104192,"accession_number":"0001104659-26-006813","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics completes Type C FDA meeting for zervimesine in DLB; discusses Phase 2b endpoints","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Type C meeting with FDA held on Jan 21, 2026 for zervimesine (CT1812) in dementia with Lewy bodies.","Discussed clinically meaningful endpoints for proposed Phase 2b study in mild-to-moderate DLB.","FDA meeting minutes expected later this quarter; no specific outcome disclosed.","Zervimesine is an oral once-daily investigational drug targeting Aβ and α-synuclein toxicity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120486,"accession_number":"0001104659-25-122555","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Cognition Therapeutics enters $75M ATM offering with Jefferies, terminates prior $40M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM sales agreement with Jefferies LLC for up to $75M of common stock (December 18, 2025).","Jefferies receives 3.0% commission on gross proceeds of any shares sold under the agreement.","Terminated prior ATM sales agreement with Cantor Fitzgerald & B. Riley effective Dec 18; ~$12.5M remained unsold.","Company retains discretion over timing and amount of sales; no minimum offering required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120485,"accession_number":"0001104659-25-107390","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics Q3 net loss narrows to $4.9M; secures $30M offering for zervimesine development","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.","Cash, equivalents & restricted cash $39.8M; plus $36.3M in NIH grant funds; runway into Q2 2027.","Closed $30M registered direct offering of 14.7M shares to institutional investors.","FDA aligned on registrational path for zervimesine (CT1812) in Alzheimer's disease.","Phase 2 START study >75% enrolled; expanded access program for dementia with Lewy bodies ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137053,"accession_number":"0001104659-25-089737","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics' investor deck highlights Zervimesine Phase 3 progress","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation focuses on Zervimesine, a once-daily oral therapeutic for neurodegenerative diseases.","Zervimesine is described as advancing toward Phase 3, but no specific trial dates or results disclosed.","No financial results, guidance, or material operational updates included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137052,"accession_number":"0001104659-25-084845","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cognition Therapeutics raises ~$30.1M via registered direct offering of 14.7M shares at $2.05/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $30.1M from sale of 14.7M shares at $2.05/share in a registered direct offering.","Offering expected to close on or about August 29, 2025; Titan Partners is sole placement agent.","Placement agent fee 7.0% of gross proceeds plus warrants for 514,500 shares at $2.78 exercise price.","60-day lock-up on securities sales by the company, directors, and executive officers after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137051,"accession_number":"0001104659-25-083059","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cognition Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Aug 26, 2025, Nasdaq confirmed Cognition Therapeutics regained compliance with the $1.00 minimum bid price rule.","Stock had closed above $1.00 for more than 10 consecutive trading days as of Aug 25, 2025.","Company previously received deficiency notice on Sep 12, 2024 for bid price below $1.00 for 30 days.","Compliance removes immediate delisting risk under Nasdaq Listing Rule 5450(a)(1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137050,"accession_number":"0001104659-25-075268","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.","Cash and equivalents $11.6M; plus $41.9M in NIA grant funds; runway into Q2 2026.","Surpassed 50% enrollment in Phase 2 START study of zervimesine in early Alzheimer's.","EOP2 meeting with FDA held; breakthrough designation application for zervimesine in DLB pending.","Positive Phase 2 dry AMD data showed 28.6% reduction in GA lesion growth at 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154328,"accession_number":"0001104659-25-061142","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cognition Therapeutics shareholders elect two directors, ratify EY as auditor for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Peggy Wallace re-elected as Class I director with 8,566,458 for, 2,590,981 withheld.","Ellen B. Richstone re-elected as Class I director with 8,686,877 for, 2,470,562 withheld.","Ernst & Young ratified as independent auditor for FY 2025: 33,457,921 for, 327,242 against, 132,612 abstentions.","22,760,336 broker non-votes on director elections; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154327,"accession_number":"0001104659-25-055717","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics launches expanded access program for zervimesine in DLB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anonymous philanthropic donation from family of DLB patient who was in SHIMMER study funds the program.","Open-label EAP: 100 mg oral zervimesine daily for ~1 year; targets ~30 patients initially across 8 U.S. sites.","First site activated: Banner Sun Health Research Institute; Dr. David Shprecher site investigator; Dr. James Galvin lead investigator.","EAP open to eligible SHIMMER completers and other mild-to-moderate DLB patients meeting criteria.","Company aims to start providing zervimesine this month (June 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154326,"accession_number":"0001104659-25-055089","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics files investor presentation on pathogenic oligomers approach","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed investor presentation dated June 2025 under Item 8.01.","Presentation focuses on targeting pathogenic oligomers for neurodegenerative diseases.","No financial, clinical, or operational updates provided in the filing.","Presentation may be used in discussions with investors and analysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154325,"accession_number":"0001104659-25-045886","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.","At 18 months, mean lesion size was 28.2% smaller for zervimesine group compared to placebo.","Trial concluded early with ~100 of planned 246 enrolled; company focuses resources on Alzheimer's and DLB programs.","Dry AMD is third indication where zervimesine showed efficacy signals; oral pill vs current injectable treatments.","Additional safety, demographic, and visual outcome data still being analyzed; results to be presented at medical meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154324,"accession_number":"0001104659-25-045324","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.","Cash and equivalents $16.4M plus $47M in NIH grants; runway into Q4 2025.","Requested End-of-Phase 2 meeting with FDA to discuss Alzheimer's SHINE study and registrational trial.","Phase 2 SHIMMER study in dementia with Lewy bodies accepted for oral presentation at AAIC July 2025.","Presenting two posters at ARVO on zervimesine's role in regulating lipid metabolism and retinal cell protection."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172915,"accession_number":"0001104659-25-025828","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics reports 2024 net loss of $34M; highlights positive Phase 2 data for zervimesine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.","Net loss $34.0M ($0.86 per share) vs $25.8M ($0.86) in 2023; R&D expense $41.7M.","Phase 2 SHIMMER DLB study: up to 91% slowing vs placebo across behavior, cognition, function, movement.","Phase 2 SHINE Alzheimer's subgroup with lower p-tau217 showed near-total preservation of cognition.","Plans to request end-of-Phase 2 FDA meetings in Q2 2025 for DLB and Alzheimer's; cash runway into Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172914,"accession_number":"0001104659-25-022969","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cognition Therapeutics gets Nasdaq extension to Sept 8, 2025; transfer to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq extension notice on March 12, 2025, granting 180 additional days until Sept 8, 2025 to regain $1.00 minimum bid price.","Common stock will transfer from Nasdaq Global Market to Nasdaq Capital Market effective March 14, 2025.","Company will consider options including a reverse stock split to regain compliance.","If not compliant by Sept 8, 2025, Nasdaq will initiate delisting; company may appeal.","Bid price has been below $1.00 for over 30 consecutive business days as of Sep 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172913,"accession_number":"0001104659-25-017178","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.","MAGNIFY study enrolled 100 participants; final visits completed Feb 2025; full unblinded results expected Q2 2025.","Company concluding study early to preserve capital; plans to pursue indications in Alzheimer's and DLB.","Prior Phase 2 SHIMMER (DLB) showed 86% improvement on NPI; SHINE (Alzheimer's) showed 95% cognitive decline reduction in biomarker subgroup."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172912,"accession_number":"0001104659-25-006732","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics files corporate presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished a corporate presentation discussing its focus on targeting pathogenic oligomers for neurodegenerative diseases.","Presentation dated January 2025; no specific financial results, pipeline updates, or guidance provided in the excerpt.","Filing under Item 8.01 is a routine disclosure; no other material events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172911,"accession_number":"0001104659-25-002939","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cognition Therapeutics files investor presentation with no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an investor presentation under Item 7.01 for Regulation FD purposes.","Presentation slide titled 'Targeting Pathogenic Oligomers: A Disruptive Approach to Neurodegenerative Diseases'.","No financial results, pipeline milestones, or guidance changes are included in the filing.","Filing is a routine disclosure; no new material events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189926,"accession_number":"0001104659-24-129619","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.","Study evaluates lead candidate for Alzheimer's disease; no specific data points disclosed in the 8-K body.","Filing dated December 18, 2024; presentation likely includes efficacy/safety findings but details are unreadable.","Company undertakes no obligation to update the materials; investor attention should review the full presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189925,"accession_number":"0001104659-24-117243","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.","CT1812 showed 95% slowing of cognitive decline (ADAS-Cog11) in Alzheimer's patients with low p-tau217 at CTAD.","On track to report Phase 2 SHIMMER topline results in dementia with Lewy bodies by end of 2024.","Plans to request end-of-Phase 2 FDA meeting for CT1812 Alzheimer's program.","Cash runway into Q2 2025; R&D expense $11.4M, G&A $3.1M both flat YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189924,"accession_number":"0001104659-24-104541","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cognition Therapeutics furnishes investor presentation on amyloid beta oligomer approach","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation titled 'Targeting Amyloid Beta Oligomers: A Disruptive Approach to the Treatment of CNS Disorders' dated September 2024 made available.","No specific financial results, clinical data, or guidance changes disclosed in filing or exhibit.","Presentation furnished for Regulation FD; not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206437,"accession_number":"0001104659-24-099746","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cognition Therapeutics receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deficiency letter received on September 12, 2024; stock continues trading under CGTX.","Company has until March 11, 2025 to regain compliance under Nasdaq Rule 5450(a)(1).","If noncompliant, company may get second 180-day cure period upon transfer to Nasdaq Capital Market.","No assurance of regaining compliance; delisting could occur if not cured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206436,"accession_number":"0001104659-24-093660","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cognition Therapeutics furnishes investor presentation with no new material facts disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an investor presentation under Item 7.01 on August 28, 2024.","Presentation cover titled 'Targeting Amyloid Beta Oligomers: A Disruptive Approach to the Treatment of Alzheimer’s Disease'.","No specific financial or clinical data from the presentation are included in the filing.","Presentation is furnished, not filed, and not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206435,"accession_number":"0001104659-24-087001","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.","Cash and equivalents $28.5M as of June 30, 2024; NIA grant funds remaining $57.3M.","Net loss $7.0M for Q2 2024 vs $4.7M for Q2 2023.","Topline results from SHIMMER study in DLB expected by year-end 2024.","Company planning next phase of Alzheimer's development after SHINE results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206434,"accession_number":"0001104659-24-083280","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cognition Therapeutics files investor presentation on Phase 2 SHINE results for CT1812 Alzheimer's study","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Phase 2 proof-of-concept SHINE study of CT1812 in mild-to-moderate Alzheimer's disease.","Results presented on July 29, 2024 via investor presentation filed as exhibit.","No specific efficacy or safety endpoints disclosed in the 8-K filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223580,"accession_number":"0001104659-24-069635","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders elect Khattar and Monia as Class III directors at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jack A. Khattar elected with 13,573,718 votes for, 2,573,793 withheld, 8,421,943 broker non-votes.","Brett P. Monia, Ph.D. elected with 15,650,742 votes for, 496,769 withheld, 8,421,943 broker non-votes.","Ratification of Ernst & Young LLP as independent auditor passed: 23,994,293 for, 301,998 against, 273,163 abstentions.","Annual meeting held virtually on June 7, 2024; proposals described in proxy filed April 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223579,"accession_number":"0001104659-24-057711","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.","Cash and equivalents $34.7M plus $62.3M in NIA grant funds; sufficient through Q2 2025.","R&D expenses rose to $10.6M from $5.4M, driven by Phase 2 trial activities.","Topline SHINE (Alzheimer's) results expected mid-2024; SHIMMER (DLB) enrolled 130 participants.","Completed follow-on offering in March 2024, netting $11.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243013,"accession_number":"0001104659-24-038686","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cognition Therapeutics reports FY2023 net loss of $25.8M, cash runway through May 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.8M ($0.86 per share) for FY2023 vs $21.4M ($0.91 per share) in FY2022.","Cash and equivalents $29.9M at Dec 31, 2023; NIA grant funds of $67.5M remain available.","March 2024 follow-on offering raised ~$10.4M net, extending cash runway through May 2025.","Topline results from Phase 2 SHINE study (Alzheimer's) expected mid-2024; SHIMMER (DLB) in 2H2024.","R&D expenses rose to $37.2M from $30.3M, mainly due to Phase 2 trial activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243012,"accession_number":"0001104659-24-033923","cik":1455365,"company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cognition Therapeutics raises ~$10.4M in public offering of 6.57M shares at $1.75","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 6,571,428 shares of common stock at $1.75 per share; net proceeds ~$10.4M after expenses.","Underwriter granted 30-day option to buy up to 985,714 additional shares at the same price.","Offering expected to close March 14, 2024; funds to be used for R&D, clinical development, manufacturing, and working capital.","Directors and executive officers subject to lock-up agreements prohibiting share sales until May 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":108292605.42016809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}